Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3013MR)

This product GTTS-WQ3013MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7&ITGAE gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000885.6; NM_000889.3; NM_002208.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695; 3682
UniProt ID P13612; P26010; P38570
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3013MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11058MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ5380MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ10701MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ5258MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ9017MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ6948MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ8974MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ6506MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CX-072
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW